GO:0036029 protein C inhibitor-KLK3 complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0036029 describes a heterodimeric protein complex formed by protein C inhibitor (SERPINA5) and prostate-specific antigen (KLK3).
• Formation of the SERPINA5-KLK3 complex inhibits the serine protease activity of KLK3, a key regulator of semen liquefaction and prostate biology.
• The complex is part of the broader protein C system, which includes anticoagulant and protease-inhibitory functions.
• SERPINA5 is a multifunctional serpin that also inhibits activated protein C and other proteases, linking the complex to coagulation and inflammation.
• Dysregulation of KLK3 and SERPINA5 has been implicated in prostate cancer and hypercoagulable states.
• Studying this complex requires tools such as knockout, point-mutation, and knock-in cell models, along with proteomic and biochemical assays.
Description
The protein C inhibitor-KLK3 complex (GO:0036029) is a heterodimeric cellular component formed by the high-affinity binding of protein C inhibitor (SERPINA5) to prostate-specific antigen (KLK3). This interaction is a classic example of serpin-protease complex formation, where the serpin inhibits the target protease by trapping it in a stable, inactive complex. The complex is part of the protein C pathway, a major anticoagulant and anti-inflammatory system. Understanding this complex is important because it connects hemostasis, male fertility, and prostate cancer biology. Researchers study GO:0036029 to dissect how SERPINA5 regulates KLK3 activity and how this regulation is altered in disease.
protein C inhibitor-KLK3 complex At A Glance
| GO ID | GO:0036029 |
|---|---|
| GO term | protein C inhibitor-KLK3 complex |
| Ontology | cellular_component |
| Synonym | PCI-KLK3 complex; SERPINA5-KLK3 complex; protein C inhibitor-prostate-specific antigen complex |
| Major function | Inhibition of KLK3 serine protease activity through stable complex formation |
| Complex type | Heterodimer of SERPINA5 and KLK3 |
| Related pathway | Protein C pathway and serpin-protease regulation |
| Disease relevance | Prostate cancer, hypercoagulable states, aortic aneurysms |
What Is GO:0036029?
According to the Gene Ontology, GO:0036029 is a cellular component defined as a heterodimeric protein complex that contains protein C inhibitor (SERPINA5) and prostate-specific antigen (KLK3); formation of the complex inhibits the serine protease activity of prostate-specific antigen. In simpler terms, it is the molecular handcuff that SERPINA5 puts on KLK3 to stop its protease function.
Why Is protein C inhibitor-KLK3 complex Important in Cell Biology?
The protein C inhibitor-KLK3 complex is a critical node at the intersection of coagulation, inflammation, and prostate biology. Because SERPINA5 is a multifunctional serpin that also inhibits activated protein C, its interaction with KLK3 can influence both local protease activity and systemic hemostatic balance. Dysregulated complex formation may contribute to prostate cancer progression and thrombotic disorders, making it a target for biomarker and therapeutic research.
• Regulates KLK3 (prostate-specific antigen) activity, a key biomarker in prostate cancer.
• Links the protein C anticoagulant pathway to prostate physiology.
• SERPINA5 is a multifunctional serpin with roles in coagulation and inflammation.
• Complex formation may be altered in hypercoagulable states.
• Activated protein C-protein C inhibitor complexes are markers for vascular disease.
• Provides a model for studying serpin-protease inhibitory mechanisms.
• Potential target for prostate cancer diagnostics and therapeutics.
• Relevant to male fertility due to KLK3 role in semen liquefaction.
• Connects to broader protein C pathway research in thrombosis and inflammation.
• Enables development of CRISPR models to dissect gene function.
Structure and Composition of protein C inhibitor-KLK3 complex
SERPINA5 (Protein C Inhibitor)
In simple terms: SERPINA5 is the 'handcuff' protein that grabs KLK3.
SERPINA5, also known as protein C inhibitor, is a member of the serpin superfamily and is a multifunctional inhibitor of serine proteases. It is synthesized primarily in the liver and also in reproductive tissues, and it circulates in plasma as well as in seminal fluid. SERPINA5 contains a reactive center loop that acts as a bait for target proteases, including KLK3 and activated protein C.
KLK3 (Prostate-Specific Antigen)
In simple terms: KLK3 is a protease enzyme that becomes inactive when bound by SERPINA5.
KLK3, also known as prostate-specific antigen (PSA), is a serine protease produced by prostate epithelial cells. Its primary physiological function is to liquefy semen by cleaving seminogelin, but it also has roles in prostate cancer progression. KLK3 is a member of the kallikrein-related peptidase family and is a well-established biomarker for prostate cancer.
Complex Assembly
In simple terms: SERPINA5 and KLK3 bind together to form a stable, inactive pair.
The formation of the SERPINA5-KLK3 complex occurs through the interaction of the SERPINA5 reactive center loop with the active site of KLK3. This results in a covalent acyl-enzyme intermediate that rearranges into a stable, irreversible complex, effectively inhibiting KLK3 protease activity. The complex is a heterodimer and is classified as a cellular component in the Gene Ontology.
Stoichiometry and Stability
In simple terms: One SERPINA5 molecule binds one KLK3 molecule to form a stable complex.
The complex is formed in a 1:1 stoichiometry, with SERPINA5 acting as a suicide substrate inhibitor. Once formed, the complex is stable and can be detected in biological fluids, including seminal plasma and blood. The stability of the complex makes it a useful marker for protease inhibition in vivo.
Key Genes Involved in GO:0036029 protein C inhibitor-KLK3 complex
The following genes and proteins are directly or indirectly involved in the formation, regulation, and function of the protein C inhibitor-KLK3 complex.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SERPINA5 | Protein C inhibitor; forms complex with KLK3 and inhibits its protease activity | Target for studying serpin-protease interactions and coagulation |
| KLK3 | Prostate-specific antigen; serine protease inhibited by SERPINA5 | Biomarker for prostate cancer and target for CRISPR knockout |
| PROC | Protein C; precursor of activated protein C, which is also inhibited by SERPINA5 | Central to anticoagulant pathway research |
| PROCR | Endothelial protein C receptor; enhances protein C activation | Modulates protein C pathway activity |
| F5 | Factor V; cofactor in coagulation, mutated in factor V Leiden | Relevant to hypercoagulable states |
| F2 | Prothrombin; precursor of thrombin, which activates protein C | Key coagulation factor |
| SERPINC1 | Antithrombin; major anticoagulant | Controls thrombin and other proteases |
| PLG | Plasminogen; precursor of plasmin, involved in fibrinolysis | Interacts with KLK3 in semen liquefaction |
| KLK2 | Kallikrein-related peptidase 2; related to KLK3 | May compensate for KLK3 function |
| TFPI | Tissue factor pathway inhibitor; regulates coagulation initiation | Indirectly affects protein C pathway |
| THBD | Thrombomodulin; cofactor for protein C activation | Endothelial anticoagulant |
| EPCR | Endothelial protein C receptor; accelerates protein C activation | Modulates pathway |
| SERPINE1 | Plasminogen activator inhibitor-1; regulates fibrinolysis | Linked to thrombosis |
| F8 | Factor VIII; cofactor in coagulation | Deficiency causes hemophilia A |
| F9 | Factor IX; serine protease in coagulation | Deficiency causes hemophilia B |
| F10 | Factor X; serine protease in coagulation | Central to thrombin generation |
| F11 | Factor XI; serine protease in coagulation | Involved in intrinsic pathway |
How Is protein C inhibitor-KLK3 complex Regulated?
The formation of the protein C inhibitor-KLK3 complex is regulated by the availability of both SERPINA5 and KLK3, as well as by the local environment. SERPINA5 levels are influenced by hormonal and inflammatory signals, while KLK3 expression is androgen-regulated in prostate cells. The protein C pathway itself is tightly regulated by cofactors such as thrombomodulin and the endothelial protein C receptor, which modulate the activation of protein C and its subsequent inhibition by SERPINA5. Additionally, the complex is part of a broader network of serpin-protease interactions that maintain hemostatic balance.
protein C inhibitor-KLK3 complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SERPINA5 | Prostate cancer, thrombosis | CRISPR knockout in prostate cancer cell lines (e.g., LNCaP) |
| KLK3 | Prostate cancer, semen liquefaction | KLK3 knockout or point-mutation in prostate cells |
| PROC | Thrombophilia, sepsis | PROC knockout mice or cell models |
| F5 | Factor V Leiden thrombophilia | Point-mutation knock-in in hepatocytes |
| F2 | Prothrombin-related thrombosis | Knock-in of prothrombin mutations |
Prostate Cancer
KLK3 (PSA) is the most widely used biomarker for prostate cancer, and its regulation by SERPINA5 may influence tumor progression. The formation of the SERPINA5-KLK3 complex reduces KLK3 protease activity, which could affect cancer cell invasion and metastasis. Studies have shown that SERPINA5 expression is altered in prostate cancer, suggesting a role in disease pathogenesis.
Thrombotic Disorders
SERPINA5 is a key inhibitor of activated protein C, and the protein C pathway is critical for preventing thrombosis. Elevated levels of activated protein C-protein C inhibitor complexes have been observed in hypercoagulable states and aortic aneurysms. Thus, the protein C inhibitor-KLK3 complex may serve as a marker or modulator of thrombotic risk.
Inflammatory and Vascular Diseases
The protein C pathway has anti-inflammatory properties, and SERPINA5 can modulate these effects. Dysregulation of the complex may contribute to vascular inflammation and aneurysm formation. Further research is needed to fully elucidate the role of the SERPINA5-KLK3 complex in these conditions.
From protein C inhibitor-KLK3 complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SERPINA5 inhibit KLK3 in prostate cells? | SERPINA5 knockout in LNCaP cells |
| Does KLK3 mutation affect complex formation? | KLK3 point-mutation knock-in in PC-3 cells |
| Can SERPINA5 overexpression reduce KLK3 activity? | SERPINA5 overexpression in prostate cancer cell lines |
| What is the role of SERPINA5 in coagulation? | SERPINA5 knockout in hepatocytes or mouse models |
| How does the complex affect thrombosis? | Activated protein C-protein C inhibitor complex measurement in patient plasma |
| Does KLK3 cleavage of seminogelin require SERPINA5 regulation? | KLK3 knockout in seminal vesicle cells |
How to Study the protein C inhibitor-KLK3 complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot | Presence of SERPINA5-KLK3 complex | Detection in cell lysates |
| ELISA | Quantification of complex or free KLK3 | Clinical biomarker studies |
| Mass spectrometry | Identification of complex components | Proteomic profiling |
| CRISPR knockout | Loss of gene function | Target validation |
| CRISPR point mutation | Specific amino acid changes | Structure-function studies |
| CRISPR knock-in | Tagged or mutant protein expression | Live-cell imaging |
| Enzyme activity assay | KLK3 protease activity | Inhibitor screening |
Biochemical Assays for Complex Formation
The formation of the SERPINA5-KLK3 complex can be studied using gel electrophoresis, immunoblotting, and enzyme activity assays. These methods allow researchers to detect the stable complex and measure the inhibition of KLK3 protease activity.
Proteomic and Mass Spectrometry Approaches
Mass spectrometry-based proteomics can identify and quantify the SERPINA5-KLK3 complex in biological samples. This approach is useful for detecting post-translational modifications and for biomarker discovery.
CRISPR-Cas9 Genome Editing
CRISPR-Cas9 can be used to generate knockout, point-mutation, and knock-in cell models to study the function of SERPINA5 and KLK3. These models enable precise dissection of the complex's role in disease.
Clinical Biomarker Measurement
Levels of activated protein C-protein C inhibitor complexes can be measured in plasma as a marker of hypercoagulable states. Similar assays could be adapted for the SERPINA5-KLK3 complex.
How CRISPR Can Be Used to Study GO:0036029 protein C inhibitor-KLK3 complex
Knockout
CRISPR knockout of SERPINA5 or KLK3 can abolish complex formation, allowing researchers to study the downstream effects on protease activity and cellular phenotypes. For example, SERPINA5 knockout in prostate cancer cells may increase KLK3 activity and affect invasion.
Point Mutation
Point mutations in the reactive center loop of SERPINA5 or the active site of KLK3 can disrupt complex formation, providing insights into the molecular determinants of binding. Such models are valuable for dissecting serpin-protease specificity.
Knock-in
Knock-in of tagged versions of SERPINA5 or KLK3 (e.g., GFP or HA tags) enables live-cell imaging and pull-down assays to track complex formation and localization. This approach can reveal real-time dynamics of the interaction.
Overexpression
Overexpression of SERPINA5 or KLK3 can be achieved via CRISPR activation or lentiviral delivery, allowing researchers to study the effects of elevated protein levels on complex formation and disease phenotypes. This is particularly useful for modeling prostate cancer progression.
How EDITGENE Supports protein C inhibitor-KLK3 complex Research
Researchers studying protein C inhibitor-KLK3 complex-related genes often need to determine whether a candidate gene is causally involved in complex formation, protease inhibition, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for protein C inhibitor-KLK3 complex research.
Frequently Asked Questions About protein C inhibitor-KLK3 complex
What is the protein C inhibitor-KLK3 complex?
It is a heterodimeric protein complex formed by SERPINA5 and KLK3, which inhibits KLK3 protease activity.
What genes are involved in the protein C inhibitor-KLK3 complex?
The main genes are SERPINA5 (protein C inhibitor) and KLK3 (prostate-specific antigen).
What is the function of GO:0036029?
GO:0036029 describes a cellular component that inhibits the serine protease activity of KLK3 through complex formation.
How is the protein C inhibitor-KLK3 complex formed?
SERPINA5 binds to the active site of KLK3, forming a stable covalent complex that inactivates the protease.
What diseases are associated with the protein C inhibitor-KLK3 complex?
It has been linked to prostate cancer and thrombotic disorders.
Is the protein C inhibitor-KLK3 complex a biomarker?
Components of the complex, such as activated protein C-protein C inhibitor, have been studied as biomarkers for hypercoagulable states.
How can CRISPR be used to study the protein C inhibitor-KLK3 complex?
CRISPR can generate knockout, point-mutation, and knock-in models to dissect the roles of SERPINA5 and KLK3.
What is the relationship between SERPINA5 and KLK3?
SERPINA5 is a serpin that inhibits KLK3, a serine protease, by forming a stable complex.
What are the synonyms for GO:0036029?
Synonyms include PCI-KLK3 complex, SERPINA5-KLK3 complex, and protein C inhibitor-prostate-specific antigen complex.
Why is the protein C inhibitor-KLK3 complex important in cancer?
KLK3 is a major prostate cancer biomarker, and its regulation by SERPINA5 may influence tumor progression.
Conclusion
The protein C inhibitor-KLK3 complex (GO:0036029) is a well-defined heterodimeric cellular component that plays a crucial role in regulating KLK3 protease activity. Its involvement in prostate cancer and thrombotic disorders makes it a compelling target for basic and translational research. By leveraging CRISPR-based models and biochemical assays, researchers can further unravel the molecular mechanisms and disease relevance of this complex.
References
- 1. Kubier A et al.. 2012. Endogenous anticoagulants.. Top Companion Anim Med 27(2):81-7 PMID: 23031460
- 2. Norris LA. 2003. Blood coagulation.. Best Pract Res Clin Obstet Gynaecol 17(3):369-83 PMID: 12787532
- 3. Esmon CT. 2003. The protein C pathway.. Chest 124(3 Suppl):26S-32S PMID: 12970121
- 4. Kölbel T et al.. 2006. Activated protein C-protein C inhibitor complex: a new biological marker for aortic aneurysms.. J Vasc Surg 43(5):935-9 PMID: 16678686
- 5. Espana F et al.. 2005. The multifunctional protein C system.. Curr Med Chem Cardiovasc Hematol Agents 3(2):119-31 PMID: 15853699
- 6. Dahlbäck B et al.. 2005. The anticoagulant protein C pathway.. FEBS Lett 579(15):3310-6 PMID: 15943976
- 8. Watanabe R et al.. 2000. Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.. Am J Hematol 65(1):35-40 PMID: 10936861
